Summary & Overview
HCPCS Q4240: Corecyte Topical Biologic, per 0.5 cc
HCPCS Level II code Q4240 denotes Corecyte, a topical biologic product supplied in 0.5 cc units for topical use. This product is used in dermatologic and wound-care contexts and is billed when the topical formulation is applied to a specific skin or wound area. Nationally, a discrete HCPCS Level II code for a topical biologic supports standardized reporting, payer adjudication, and supply tracking across ambulatory and outpatient settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for topical biologic use, common billing considerations tied to unitization (per 0.5 cc), and how the code is typically applied in outpatient and wound-care sites. The publication also summarizes common modifiers and operational notes for claims processing, highlights typical settings where the product is used, and points readers to where to look for coverage policies and medical necessity criteria. Data not available in the input for payer-specific rates, associated taxonomies, and ICD-10 pairings are noted as unavailable.
Billing Code Overview
HCPCS Level II code Q4240 describes Corecyte, for topical use only, per 0.5 cc. This code represents a topical biologic product intended for localized application to a patient's skin or wound surface. Service type: topical biologic/dermal application. Typical site of service: outpatient clinic, physician office, wound care center, or other ambulatory care settings where topical treatments are applied.
Clinical & Coding Specifications
Clinical Context
A patient with a localized chronic wound or dermatologic defect presents to an outpatient specialty clinic (dermatology, wound care, or plastic surgery) for topical biologic therapy. Corecyte, a topical regenerative product supplied in 0.5 cc units (Q4240 per 0.5 cc), is selected to promote tissue repair. The typical workflow: initial evaluation and wound measurement by the specialist, wound bed preparation including debridement if indicated, documentation of baseline wound characteristics and photographs, application of the prescribed volume of Corecyte to the wound surface under sterile technique, and dressing placement. Follow-up visits occur at regular intervals to assess wound response, repeat applications as clinically indicated, and to document progress and any complications. Usual sites of service include outpatient clinics, physician offices, ambulatory surgical centers for more complex wound management, and long-term care facilities when topical application is performed on site.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or intensity significantly exceeds typical for topical application of a biologic product. |
23 |